I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms|Breast Cancer|Breast Tumors|Angiosarcoma|TNBC - Triple-Negative Breast Cancer|HER2-positive Breast Cancer|HER2-negative Breast Cancer|Hormone Receptor Positive Tumor|Hormone Receptor Negative Tumor|Early-stage Breast Cancer|Locally Advanced Breast Cancer
Interventions: DRUG: Standard Therapy|DRUG: AMG 386 with or without Trastuzumab|DRUG: AMG 479 (Ganitumab) plus Metformin|DRUG: MK-2206 with or without Trastuzumab|DRUG: AMG 386 and Trastuzumab|DRUG: T-DM1 and Pertuzumab|DRUG: Pertuzumab and Trastuzumab|DRUG: Ganetespib|DRUG: ABT-888|DRUG: Neratinib|DRUG: PLX3397|DRUG: Pembrolizumab - 4 cycle|DRUG: Talazoparib plus Irinotecan|DRUG: Patritumab and Trastuzumab|DRUG: Pembrolizumab - 8 cycle|DRUG: SGN-LIV1A|DRUG: Durvalumab plus Olaparib|DRUG: SD-101 + Pembrolizumab|DRUG: Tucatinib plus trastuzumab and pertuzumab|DRUG: Cemiplimab|DRUG: Cemiplimab plus REGN3767|DRUG: Trilaciclib with or without trastuzumab + pertuzumab|DRUG: SYD985 ([vic-]trastuzumab duocarmazine)|DRUG: Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab|DRUG: Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab|DRUG: Amcenestrant|DRUG: Amcenestrant + Abemaciclib|DRUG: Amcenestrant + Letrozole|DRUG: ARX788|DRUG: ARX788 + Cemiplimab|DRUG: VV1 + Cemiplimab|DRUG: Datopotamab deruxtecan|DRUG: Datopotamab deruxtecan + Durvalumab|DRUG: Zanidatamab|DRUG: Lasofoxifene|DRUG: Z-endoxifen|DRUG: ARV-471|DRUG: ARV-471 + Letrozole
Sponsor: QuantumLeap Healthcare Collaborative